These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25900171)

  • 21. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oritavancin for skin infections.
    Anderson DL
    Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?
    Tsoulas C; Nathwani D
    Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oritavancin: a new avenue for resistant Gram-positive bacteria.
    Mercier RC; Hrebickova L
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
    Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo antibacterial activity and pharmacological properties of the membrane-active glycopeptide antibiotic YV11455.
    Yarlagadda V; Konai MM; Manjunath GB; Prakash RG; Mani B; Paramanandham K; Ranjan SB; Ravikumar R; Chakraborty SP; Roy S; Haldar J
    Int J Antimicrob Agents; 2015 Jun; 45(6):627-34. PubMed ID: 25900818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
    Ambrose PG; Drusano GL; Craig WA
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S220-8. PubMed ID: 22431852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.
    Delaportas DJ; Estrada SJ; Darmelio M
    Pharmacotherapy; 2017 Aug; 37(8):e90-e92. PubMed ID: 28543367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
    Münch D; Engels I; Müller A; Reder-Christ K; Falkenstein-Paul H; Bierbaum G; Grein F; Bendas G; Sahl HG; Schneider T
    Antimicrob Agents Chemother; 2015 Feb; 59(2):772-81. PubMed ID: 25403671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
    Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.
    Dunbar LM; Milata J; McClure T; Wasilewski MM;
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3476-84. PubMed ID: 21537018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
    Jame W; Basgut B; Abdi A
    PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy.
    Van Bambeke F
    Curr Opin Investig Drugs; 2006 Aug; 7(8):740-9. PubMed ID: 16955686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
    Napolitano LM
    Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013.
    Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):311-5. PubMed ID: 25294303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13).
    Mendes RE; Farrell DJ; Sader HS; Flamm RK; Jones RN
    J Antimicrob Chemother; 2015 Feb; 70(2):498-504. PubMed ID: 25362568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
    Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.